Carderock Capital Management Decreased Mettler Toledo Intl (MTD) Position By $453,348; Epizyme Has 1.93 Sentiment

October 6, 2017 - By Nellie Frank

Epizyme, Inc. is a clinical-stage biopharmaceutical company. The company has market cap of $1.24 billion. The Firm discovers, develops and plans to commercialize epigenetic therapies for cancer patients. It currently has negative earnings. The Firm is engaged in the discovery and development of novel epigenetic therapies for cancer patients.

Carderock Capital Management Inc decreased Mettler Toledo Intl (MTD) stake by 9.39% reported in 2017Q2 SEC filing. Carderock Capital Management Inc sold 771 shares as Mettler Toledo Intl (MTD)’s stock rose 19.62%. The Carderock Capital Management Inc holds 7,436 shares with $4.38M value, down from 8,207 last quarter. Mettler Toledo Intl now has $16.56 billion valuation. The stock rose 0.03% or $0.19 reaching $645.04. About 18,196 shares traded. Mettler-Toledo International Inc. (NYSE:MTD) has risen 55.25% since October 6, 2016 and is uptrending. It has outperformed by 38.55% the S&P500.

Among 7 analysts covering Mettler-toledo International Inc. (NYSE:MTD), 3 have Buy rating, 0 Sell and 4 Hold. Therefore 43% are positive. Mettler-toledo International Inc. had 16 analyst reports since August 3, 2015 according to SRatingsIntel. The rating was downgraded by UBS on Friday, August 5 to “Neutral”. The company was downgraded on Thursday, September 10 by Bank of America. Goldman Sachs initiated Mettler-Toledo International Inc. (NYSE:MTD) on Tuesday, September 26 with “Buy” rating. The company was maintained on Tuesday, June 20 by Jefferies. The firm earned “Buy” rating on Wednesday, August 31 by Bank of America. The firm has “Outperform” rating by Wells Fargo given on Thursday, July 13. Jefferies maintained Mettler-Toledo International Inc. (NYSE:MTD) on Thursday, August 31 with “Hold” rating. As per Thursday, June 23, the company rating was downgraded by Citigroup. Citigroup upgraded Mettler-Toledo International Inc. (NYSE:MTD) on Tuesday, September 8 to “Buy” rating.

Investors sentiment decreased to 0.91 in Q2 2017. Its down 0.13, from 1.04 in 2017Q1. It is negative, as 26 investors sold MTD shares while 180 reduced holdings. 73 funds opened positions while 115 raised stakes. 23.46 million shares or 0.29% less from 23.53 million shares in 2017Q1 were reported. Sumitomo Mitsui Trust Holding stated it has 78,434 shares or 0.07% of all its holdings. Lmr Ptnrs Llp accumulated 0.16% or 4,340 shares. Federated Invsts Pa has invested 0.03% in Mettler-Toledo International Inc. (NYSE:MTD). Chevy Chase Tru Holdg owns 0.06% invested in Mettler-Toledo International Inc. (NYSE:MTD) for 22,395 shares. 1.86M are owned by Blackrock Inc. Oregon Pub Employees Retirement Fund reported 12,772 shares. 96,295 were reported by Dimensional Fund Advsrs L P. Wetherby Asset Mngmt holds 0.08% or 847 shares. Twin Tree Lp owns 7 shares. State Teachers Retirement Systems stated it has 41,201 shares or 0.06% of all its holdings. Aureus Asset Mgmt Limited Liability Co, a Massachusetts-based fund reported 720 shares. Hartford Mngmt Co accumulated 5,530 shares or 0.06% of the stock. Ashfield Capital Prtnrs holds 0.36% or 4,487 shares in its portfolio. Louisiana State Employees Retirement System, a Louisiana-based fund reported 1,600 shares. Moreover, Albert D Mason has 1.62% invested in Mettler-Toledo International Inc. (NYSE:MTD) for 3,298 shares.

Analysts await Mettler-Toledo International Inc. (NYSE:MTD) to report earnings on November, 2. They expect $4.32 EPS, up 11.05% or $0.43 from last year’s $3.89 per share. MTD’s profit will be $110.91 million for 37.33 P/E if the $4.32 EPS becomes a reality. After $3.92 actual EPS reported by Mettler-Toledo International Inc. for the previous quarter, Wall Street now forecasts 10.20% EPS growth.

Since May 8, 2017, it had 0 insider purchases, and 18 selling transactions for $36.45 million activity. 2,000 shares valued at $1.11M were sold by Caratsch Thomas on Monday, May 15. $3.53M worth of Mettler-Toledo International Inc. (NYSE:MTD) shares were sold by SPOERRY ROBERT F. 811 shares valued at $475,270 were sold by Kirk Simon on Thursday, June 1. DONNELLY WILLIAM P also sold $2.73M worth of Mettler-Toledo International Inc. (NYSE:MTD) shares. CONTINO FRANCIS A had sold 725 shares worth $395,850. The insider FILLIOL OLIVER A sold $11.97M. Chu Wah-Hui had sold 500 shares worth $283,500 on Monday, May 22.

Foresite Capital Management Ii Llc holds 10.27% of its portfolio in Epizyme Inc for 1.48 million shares. Palo Alto Investors Llc owns 5.70 million shares or 4.02% of their US portfolio. Moreover, Nea Management Company Llc has 3.44% invested in the company for 6.26 million shares. The Maryland-based Rock Springs Capital Management Lp has invested 0.9% in the stock. Oracle Investment Management Inc, a Connecticut-based fund reported 292,380 shares.

Since January 1, 0001, it had 0 buys, and 3 insider sales for $362,502 activity.

Analysts await Epizyme Inc (NASDAQ:EPZM) to report earnings on November, 2. They expect $-0.66 earnings per share, down 57.14% or $0.24 from last year’s $-0.42 per share. After $-0.48 actual earnings per share reported by Epizyme Inc for the previous quarter, Wall Street now forecasts 37.50% negative EPS growth.

About 180,935 shares traded. Epizyme Inc (EPZM) has risen 91.85% since October 6, 2016 and is uptrending. It has outperformed by 75.15% the S&P500.